InicioAPNHY • OTCMKTS
add
Aspen Pharmacare Holdings ADR
Cierre anterior
9,42 $
Intervalo diario
9,65 $ - 9,65 $
Intervalo anual
9,42 $ - 13,69 $
Cap. bursátil
75,89 mil M ZAR
Volumen medio
174,00
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (ZAR) | jun 2024info | Cambio interanual |
|---|---|---|
Ingresos | 11,78 mil M | 9,30 % |
Gastos operativos | 2356,00 M | -3,24 % |
Ingresos netos | 1045,00 M | -18,17 % |
Margen de beneficio neto | 8,87 | -25,15 % |
Beneficios por acción | — | — |
EBITDA | 2928,50 M | 7,80 % |
Tipo impositivo efectivo | 25,52 % | — |
Balance general
Activos totales
Responsabilidades totales
| (ZAR) | jun 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 12,34 mil M | 13,06 % |
Activos totales | 139,16 mil M | 3,63 % |
Responsabilidades totales | 54,29 mil M | 13,00 % |
Patrimonio total | 84,86 mil M | — |
Acciones en circulación | 444,21 M | — |
Precio-valor contable | 0,05 | — |
Rentabilidad económica | 4,84 % | — |
Retorno sobre capital | 5,56 % | — |
Flujo de caja
Variación neta del flujo de caja
| (ZAR) | jun 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | 1045,00 M | -18,17 % |
Efectivo de operaciones | 1883,50 M | -1,21 % |
Efectivo de inversión | -1649,00 M | -79,92 % |
Efectivo de financiación | -141,50 M | 52,91 % |
Variación neta del flujo de caja | -200,00 M | -118,37 % |
Flujo de caja libre | 525,31 M | -32,86 % |
Información sobre la empresa
Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union. Wikipedia
Director ejecutivo
Fundación
1850
Sitio web
Empleados
9.109
